Prothrombin Complex Concentrate Reduces Blood Product Utilization in Heart Transplantation

Area of Science:

• Cardiology
• Hematology
• Transplantation Medicine

Background:

• Warfarin reversal before cardiac surgery typically involves vitamin K and fresh frozen plasma (FFP).
• The efficacy of prothrombin complex concentrate (PCC) for warfarin reversal lacks clear consensus.
• Four-factor (4-F) PCC is increasingly considered for perioperative warfarin management.

Purpose of the Study:

• To evaluate the efficacy of 4-F PCC in reducing blood product utilization.
• To compare perioperative blood product use in patients receiving 4-F PCC versus standard care.
• To assess the impact of 4-F PCC on warfarin reversal before heart transplantation.

Main Methods:

• Retrospective cohort study comparing 21 patients receiving 4-F PCC with 39 controls.
• Blood product utilization was analyzed for 24-hour preoperative, intraoperative, and 48-hour postoperative periods.
• Data collected from January 2011 to July 2015 at a single center.

Main Results:

• Patients receiving 4-F PCC required significantly fewer blood products preoperatively (10% vs 56%, p<0.001).
• The 4-F PCC group showed reduced intraoperative use of packed red blood cells (median 3 vs 7 units, p<0.001) and FFP (median 4 vs 9 units, p<0.001).
• Postoperatively, fewer patients in the 4-F PCC group received blood products (24% vs 51%, p=0.04).

Conclusions:

• 4-F PCC administration is associated with decreased perioperative blood product utilization.
• Significant reduction in fresh frozen plasma (FFP) requirements was observed with 4-F PCC.
• 4-F PCC offers a potentially more effective strategy for warfarin reversal in cardiac surgery patients.